PEPG News and Press, PepGen Inc. From 02/23/26

Controladora Vuela Compania de Aviacion S.A.B. de C.V. American Depositary Shares each representing ten (10) Ordinary Participation Certificates (VLRS) is expected to report $0.25 for Q4 2025 Galapagos NV (GLPG) is expected to report $1 for Q4 2025 Octave Specialty Group Inc. (OSG) is exp...

2026-02-22 17:38:53 ET PepGen Inc. (PEPG) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 11.01%. The average open to low on the day of earnings was -10.00%. The average open to close on...

2026-02-22 17:33:56 ET PepGen Inc. (PEPG) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in PEPG stock price following earnings has averaged ±6.50% , with a median of 0.81%. The sing...

2026-02-02 15:17:08 ET More on healthcare stocks CMS Rates Proposal Shatters Health Insurance Stocks: What Investors Must Know (& Do) Insurers Brace For Extended 'Managed Retreat' Following 2027 MA Proposal XLV Vs. BME: Total Return Or Income, Which Healthcare St...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 In...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business...

2025-11-12 09:33:08 ET More on PepGen PepGen: Moving To "Hold" Rating On Best Mean Splicing Correction In DM1 Testing PepGen: DMD Discontinued, Ways To Go With DM1 Dyne, PepGen jump as potential beneficiaries of Novartis/Avidity deal PepGen announces pricing ...

Composition of matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal ...

– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients enrolled and having received at least one dose – – ...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...